

Ribavirin Liquid Formulation

Version 4.7	Revision Date: 28.09.2024		S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015			
SECTION	1. IDENTIFICATION						
Product identifier		:	Ribavirin Liquid Formulation				
Manu	afacturer or supplier	's detai	ils				
Comp	bany	:	MSD				
Addre	Address		Avenue Comendador Antônio Loureiro Ramos, nº 1500 – Distrito Industrial Montes Claros – MG, Brazil 39404-620				
Telephone		:	+55 (38) 3229 7000				
Emergency telephone		:	+55 (38) 320	1 5670			
E-ma	E-mail address		EHSDATASTEWARD@msd.com				
Reco	ommended use of the	e chem	ical and restri	ictions on use			
	mmended use	:	Pharmaceutic				
Restr	ictions on use	:	Not applicabl	e			

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification in accord Germ cell mutagenicity		ce with ABNT NBR 14725 Standard Category 2
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Blood)

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms	
Signal Word	Danger
Hazard Statements	H341 Suspected of causing genetic defects. H360Df May damage the unborn child. Suspected of damaging fertility. H373 May cause damage to organs (Blood) through prolonged or repeated exposure if swallowed.
Precautionary Statements	Prevention: P201 Obtain special instructions before use. P280 Wear protective gloves/ protective clothing/ eye protec-



Version 4.7	Revision Date: 28.09.2024	SDS Number: 402732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015			
tion/ face protection.						
Response:						

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Other hazards which do not result in classification None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Sucrose	57-50-1		>= 30 -< 50
Ribavirin	36791-04-5	Acute Tox. (Oral), 4 Muta., 2 Repr., 1B STOT SE, 3 STOT RE, (Oral)(Blood) , 1	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water.
		Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse.
		Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention.
Most important symptoms	:	Rinse mouth thoroughly with water. Suspected of causing genetic defects.
and effects, both acute and delayed	•	May damage the unborn child. Suspected of damaging fertility.
·		May cause damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).



Ribavirin Liquid Formulation

Vers 4.7	sion	Revision Date: 28.09.2024		9S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015
	Notes to physician		:	Treat symptomation	cally and supportively.
SEC	SECTION 5. FIRE-FIGHTING MEASURES				
Suitable extinguishing media		:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical		
	Unsuitable extinguishing media		:	None known.	
	Specific hazards during fire fighting		:	Exposure to comb	oustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides	
	Specific ods	c extinguishing meth-	:	: Use extinguishing measures that are appropriate to lo cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is so. Evacuate area.	
	Special for fire-	protective equipment fighters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- tive equipment and emer- gency procedures	Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.



Version 4.7	Revision Date: 28.09.2024	SDS Number: 402732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015				
			and 15 of this SDS provide information regarding or national requirements.				
SECTION	7. HANDLING AND ST	ORAGE					
Tech	nical measures		ring measures under EXPOSURE				
Loca	I/Total ventilation		CONTROLS/PERSONAL PROTECTION section. : If sufficient ventilation is unavailable, use with local exhaust ventilation				
Advid	ce on safe handling	: Do not get or Do not breath Do not swallo Avoid contac Wash skin th Handle in acc practice, base assessment Keep contain Do not eat, d					
Hygiene measures		flushing syste place. When using of Wash contan The effective engineering of appropriate of industrial hyg	o chemical is likely during typical use, provide eye ems and safety showers close to the working do not eat, drink or smoke. ninated clothing before re-use. operation of a facility should include review of controls, proper personal protective equipment, legowning and decontamination procedures, iene monitoring, medical surveillance and the istrative controls.				
Conc	litions for safe storage	: Keep in prop Store locked Keep tightly o	erly labeled containers. up.				
Mate	rials to avoid	: Do not store Strong oxidiz	with the following product types: ing agents substances and mixtures				

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Sucrose	57-50-1	TŴA	10 mg/m ³	ACGIH
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m3 (OEB 3)	Internal



Ribavirin Liquid Formulation

Version 4.7	Revision Date: 28.09.2024	-	0S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015		
Engi	Engineering measures		Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compour are required to control at source and to prevent migration the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.			
Pers	onal protective equip	ment				
Fi	Respiratory protection Filter type Hand protection		If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Combined particulates and organic vapor type			
Μ	laterial	:	Chemical-resista	nt gloves		
	emarks protection	:	 Consider double gloving. Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty condit mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is potential for direct contact to the face with dusts, mists, 			
Skin	Skin and body protection :		aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentiall contaminated clothing.			

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state	:	liquid
Color	:	clear
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	4,8 - 5,5
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available



Ribavirin Liquid Formulation

Vers 4.7	sion	Revision Date: 28.09.2024		S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available)
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available)
	Vapor p	oressure	:	No data available	9
	Relative	e vapor density	:	No data available	9
	Relative	e density	:	No data available)
	Density	,	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	No data available	9
		n coefficient: n-	:	Not applicable	
	octanol Autoigr	/water hition temperature	:	No data available	9
	Decom	position temperature	:	No data available)
	Viscosi Visc	ty cosity, kinematic	:	No data available	9
	Explosi	ve properties	:	Not explosive	
	Oxidizir	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Particle Particle	e characteristics e size	:	Not applicable	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products		None known. Oxidizing agents No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of	:	Inhalation
exposure		Skin contact



rsion 7	Revision Date: 28.09.2024		9S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015
			Ingestion Eye contact	
Acute	toxicity			
Not cla	assified based on availa	ble	information.	
<u>Produ</u>			A	5 000 //
Acute	oral toxicity	:	Acute toxicity esti Method: Calculati	imate: > 5.000 mg/kg ion method
<u>Comp</u>	oonents:			
Sucro	ose:			
Acute	oral toxicity	:	LD50 (Rat): 29.70	00 mg/kg
Ribav				
Acute	oral toxicity	:	LD50 (Rat): 4.116	
			LD50 (Mouse): >	
			LD50 (Dog): >= 1	.500 mg/kg
Acute	inhalation toxicity	:	Remarks: No data	a available
Acute	dermal toxicity	:	Remarks: No data	a available
	toxicity (other routes of istration)	:	LD50 (Rat): 1.554 Application Route	
			LD50 (Mouse): 1. Application Route	
Skin d	corrosion/irritation			
Not cla	assified based on availa	ble	information.	
<u>Comp</u>	oonents:			
Ribav	irin:			
Rema	rks	:	No data available May irritate skin.	
	us eye damage/eye irri assified based on availa			
	onents:	DIG		
Ribav				
Rema		:	No data available May irritate eyes.	



Ver 4.7	sion	Revision Date: 28.09.2024		98 Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015					
	Respiratory or skin sensitization									
	Skin sensitization Not classified based on available information.									
	Respiratory sensitization Not classified based on available information.									
	Components:									
Ribavirin:Remarks: No data available										
	Germ cell mutagenicity Suspected of causing genetic defects.									
	<u>Compo</u>	onents:								
	Sucros									
	Genoto	xicity in vitro		: Test Type: In vitro mammalian cell gene mutatior Result: negative						
	Ribavir	Ribavirin:								
	Genoto	xicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)					
				Test Type: In vitro Test system: Rod Result: positive	o mammalian cell gene mutation test ent cell line					
				Test Type: Chrom Test system: Hum Result: negative	nosomal aberration nan lymphocytes					
	Genoto	xicity in vivo	:	Test Type: domina Species: Rat Result: negative	ant lethal test					
				Test Type: Mouse Species: Mouse Result: positive	e Lymphoma					
				Test Type: Micror Species: Mouse Result: positive	nucleus test					
	Germ c Assess	ell mutagenicity - ment	:	Positive result(s) f mutagenicity tests	from in vivo mammalian somatic cell s.					

Carcinogenicity

Not classified based on available information.



	Revision Date: 28.09.2024	SDS Number:Date of last issue: 30.09.2023402732-00020Date of first issue: 10.12.2015
<u>Comp</u>	oonents:	
Ribay	virin•	
Species : Application Route : Exposure time : LOAEL :		: Mouse
		: Oral
		: 6 Months
		: 75 mg/kg body weight
Resul		: negative
Target Organs		: Blood, Testes
Rema		: The mechanism or mode of action may not be relevant in h
rtonio		mans.
Speci		: Rat
	cation Route	: Oral
	sure time	: 2 Years
NOAE		: 10 mg/kg body weight
Resul		: negative
Rema	irks	: The mechanism or mode of action may not be relevant in hi mans.
Speci	es	: Mouse
	cation Route	: Oral
	sure time	: 18 Months
Resul		: negative
Rema	irks	 The mechanism or mode of action may not be relevant in he mans.
Repro	oductive toxicity	
May c	-	child. Suspected of damaging fertility.
May c	lamage the unborn o conents:	child. Suspected of damaging fertility.
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	
May o <u>Comp</u> Ribay	lamage the unborn o conents:	: Test Type: Fertility
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	: Test Type: Fertility Species: Rat, male
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	: Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	: Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	: Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	: Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Rat, females
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Rat, females Application Route: Oral
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Rat, females Application Route: Oral Fertility: NOAEL: 10 mg/kg body weight
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Rat, females Application Route: Oral
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Result: positive Test Type: Fertility Species: Rat, females Application Route: Oral Fertility: NOAEL: 10 mg/kg body weight Result: Animal testing did not show any effects on fertility.
May o <u>Comp</u> Ribay	lamage the unborn o ponents: ririn:	 Test Type: Fertility Species: Rat, male Application Route: Intraperitoneal injection Fertility: LOAEL: < 20 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Mouse, male Application Route: Oral Fertility: LOAEL: 35 mg/kg body weight Symptoms: Reduced fertility Result: positive Test Type: Fertility Species: Rat, females Application Route: Oral Fertility: NOAEL: 10 mg/kg body weight



ersion .7	Revision Date: 28.09.2024		0S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015	
				e: Oral : 160 mg/kg body weight esting did not show any effects on fertility.	
Effects on fetal development		:	Test Type: Development Species: Rat, female Application Route: Oral Developmental Toxicity: LOAEL: <= 1 mg/kg body weigh Symptoms: Reduced body weight, Reduced number of v fetuses., Skeletal malformations. Result: Embryotoxic effects and adverse effects on the o spring were detected.		
			Developmental Symptoms: Red	female e: Oral Maternal: LOAEL: 1 mg/kg body weight Foxicity: LOAEL: 1 mg/kg body weight uced body weight, Skeletal malformations. oxic effects and adverse effects on the off-	
			Symptoms: Skel tions / resorption	er e: Oral Foxicity: LOAEL: 2,5 mg/kg body weight etal and visceral variations ., Total Resorp- n rate. oxic effects and adverse effects on the off-	
			Species: Rat Application Rout General Toxicity Embryo-fetal tox	ryo-fetal development e: Oral Maternal: NOAEL: 0,3 mg/kg body weight icity.: LOAEL: 1 mg/kg body weight etal malformations.	
Repro sessr	oductive toxicity - As- nent	:	fertility, based or	of adverse effects on sexual function and n animal experiments., Clear evidence of on development, based on animal	
	F-single exposure lassified based on availa	able	information.		
Com	ponents:				

Components:

Ribavirin:

Assessment

: May cause respiratory irritation.

STOT-repeated exposure

May cause damage to organs (Blood) through prolonged or repeated exposure if swallowed.



Version 4.7	Revision Date: 28.09.2024	SDS Number: 402732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015
Com	ponents:		
Route Targe	virin: es of exposure et Organs ssment	: Ingestion : Blood : Causes dan exposure.	nage to organs through prolonged or repeated
Repe	eated dose toxicity		
<u>Com</u>	ponents:		
Spec LOAI Expo		: Monkey : 30 mg/kg : 10 d : Blood, Gast	rointestinal tract
Expo		: Rat : 7,6 mg/kg : Inhalation : 90 d : Blood, Lung	S
Expo		: Dog : 5 mg/kg : Oral : 1 y : Blood, Gast	rointestinal tract
Expo		: Mouse : 20 mg/kg : Oral : 18 Months : Blood, Card	io-vascular system
-	ration toxicity classified based on av	ailable information	
	erience with human e		
	ponents:		
	virin:		
Inhal			Headache, Dizziness
	contact	: Remarks: M Based on H	ased on Human Evidence ay cause eye irritation. uman Evidence
Eye	contact		ay cause eye irritation.

 Lyb contact
 Indexternal formation may backed by a matternal back



rsion	Revision Date: 28.09.2024		9S Number: 2732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015
CTIC	ON 12. ECOLOGICAL INFO	ORN	IATION	
Γ.	- 4			
	otoxicity			
<u>Co</u>	mponents:			
	pavirin:			
То	xicity to fish	:	LC50 (Oncorhync Exposure time: 90	hus mykiss (rainbow trout)): > 119 mg/l 5 h
	xicity to daphnia and other	:		nagna (Water flea)): > 117 mg/l
aq	uatic invertebrates		Exposure time: 48 Method: OECD T	
	xicity to algae/aquatic	:		chneriella subcapitata (green algae)): > 11
pia	ints		mg/l Exposure time: 96	δh
			Method: OECD T	
			NOEC (Pseudoki	rchneriella subcapitata (green algae)): 6,9
			mg/l	
			Exposure time: 96 Method: OECD T	
То	xicity to microorganisms	:	EC50: > 1.000 mg	
			Exposure time: 3 Test Type: Respire	
			Method: OECD T	
	rsistence and degradabil	ity		
	data available			
BIG	paccumulative potential			
<u>Co</u>	mponents:			
Su	crose:			
	rtition coefficient: n- anol/water	:	Pow: < 1	
	pavirin:			
	rtition coefficient: n- anol/water	:	log Pow: 0,971	
	bility in soil			
No	data available			
	her adverse effects			
No	data available			

- **Disposal methods**
- Waste from residues

: Do not dispose of waste into sewer.



Version 4.7	Revision Date: 28.09.2024	SDS Number: 402732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015				
Co	cordance with local regulations. 's should be taken to an approved waste recycling or disposal. specified: Dispose of as unused product.						
SECTIC	ON 14. TRANSPORT INFO	RMATION					
Inte	ernational Regulations						
•	RTDG t regulated as a dangerous	s good					
	FA-DGR t regulated as a dangerous	s good					
	IMDG-Code Not regulated as a dangerous good						
	Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.						
Do	mestic regulation						
ANTT Not regulated as a dangerous good							
Special precautions for user							

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legis mixture National List of Carcinogenic Agents for Humans - (LINACH)	alation specific for the substance or
Brazil. List of chemicals controlled by the Federal Police	: Not applicable
The ingredients of this product are reported in the	following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	28.09.2024
Date format	:	dd.mm.yyyy

Further information

Sources of key data used to	:	Internal technical data, data from raw material SDSs, OECD
compile the Material Safety		eChem Portal search results and European Chemicals Agen-



Version 4.7	Revision Date: 28.09.2024	SDS Number: 402732-00020	Date of last issue: 30.09.2023 Date of first issue: 10.12.2015		
Dat	a Sheet	cy, http://echa.e	europa.eu/		
Ful	I text of other abbreviat	ons			
AC	GIH	: USA. ACGIH T	USA. ACGIH Threshold Limit Values (TLV)		
AC	GIH / TWA	: 8-hour, time-we	8-hour, time-weighted average		
ACGIH / TWA : 8-hour, time-weighted average AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transpo Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CI Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institut Standardisation; DSL - Domestic Substances List (Canada); ECX - Concentration associated x% response; ELX - Loading rate associated with x% response; EmS - Emergency Sche ENCS - Existing and New Chemical Substances (Japan); ErCX - Concentration associated tem; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; I - International Air Transport Association; IBC - International Code for the Construction Equipment of Ships carrying Dangerous Chemicals in Bulk; ICS0 - Half maximal inhibitory entration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Ch cal Substances in China; IMDG - International Maritime Dangerous Goods; IMO - Interna- daritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International anisation for Standardization; KECI - Korea Existing Chemicals Inventory; LCSO - Lethal centration to 50 % of a test population; LDSO - Lethal Dose to 50% of a test population (Me Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from S n.o.s Not Otherwise Specified; Nch - Chilean Norm; NC(A)EC - No Observable E Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIOC - Zealand Inventory of Chemicals; OECD - Organization for Exceedent Deservables (OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioacci lative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Subst es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) 1907/2006 of the European Parliament and of the Council Concerning the Registration, Evalua- Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decompo					

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specific in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8